Acumen Pharma Files 8-K for Reg FD Disclosure & Exhibits

Ticker: ABOS · Form: 8-K · Filed: Jan 12, 2024 · CIK: 1576885

Acumen Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyAcumen Pharmaceuticals, INC. (ABOS)
Form Type8-K
Filed DateJan 12, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, disclosure, corporate-governance

TL;DR

**Acumen Pharma just dropped an 8-K, likely sharing new info under Regulation FD.**

AI Summary

Acumen Pharmaceuticals, Inc. filed an 8-K on January 12, 2024, to disclose information under Regulation FD and to file financial statements and exhibits. This filing indicates that the company, trading under the symbol ABOS on The Nasdaq Global Select Market, is providing an update to the market. For investors, this matters because it signals that Acumen is actively communicating important, non-public information to the public, which could relate to operational updates, clinical trial progress, or financial developments, potentially impacting stock valuation.

Why It Matters

This filing ensures Acumen Pharmaceuticals, Inc. is transparent with investors, providing access to information that could influence investment decisions and maintain fair markets.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure filing, indicating transparency rather than a specific new risk.

Analyst Insight

Investors should review the specific content of the Regulation FD disclosure and any accompanying exhibits to understand the new information Acumen Pharmaceuticals, Inc. is sharing, as this could impact their investment thesis.

Key Players & Entities

FAQ

What is the purpose of Acumen Pharmaceuticals, Inc.'s 8-K filing on January 12, 2024?

The 8-K filing by Acumen Pharmaceuticals, Inc. on January 12, 2024, serves to disclose information under Regulation FD and to file financial statements and exhibits, as indicated by 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits'.

What is the trading symbol and the exchange where Acumen Pharmaceuticals, Inc. common stock is registered?

Acumen Pharmaceuticals, Inc.'s common stock trades under the symbol ABOS and is registered on The Nasdaq Global Select Market, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.

What is the business address and phone number of Acumen Pharmaceuticals, Inc.?

The business address for Acumen Pharmaceuticals, Inc. is 427 Park St., Charlottesville, Virginia 22902, and its telephone number is (434) 297-1000, according to the filing's 'BUSINESS ADDRESS' and 'Registrant’s Telephone Number, Including Area Code' sections.

What is the state of incorporation for Acumen Pharmaceuticals, Inc.?

Acumen Pharmaceuticals, Inc. is incorporated in Delaware, as specified under 'State or Other Jurisdiction of Incorporation' in the filing.

What is the Central Index Key (CIK) for Acumen Pharmaceuticals, Inc.?

The Central Index Key (CIK) for Acumen Pharmaceuticals, Inc. is 0001576885, as listed under 'COMPANY DATA: CENTRAL INDEX KEY' in the filing.

Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-01-12 08:42:41

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 12, 2024, Acumen Pharmaceuticals, Inc. (the " Company ") posted an updated corporate presentation to its website at https://investors.acumenpharm.com/news-events/presentations, which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Report. The information in this Item 7.01 of this Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d). Exhibits Exhibit No. Description 99.1 Corporate Presentation, dated January 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acumen Pharmaceuticals, Inc. Dated: January 12, 2024 By: /s/ Matthew Zuga Matthew Zuga Chief Financial Officer and Chief Business Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing